Pieter Sonneveld, MD, PhD

Pieter Sonneveld, MD, PhD, professor of hematology and head of the Department of Hematology at Erasmus MC Cancer Institute in The Netherlands, discusses how the findings from the phase III CASSIOPEIA trial inform current thinking about treating patients with multiple myeloma.

Sonneveld says that not only high-risk patients but all those who are transplant-eligible and newly diagnosed may potentially have a new standard of care in the future. The new standard will come from the combination of daratumumab (Darzalex) and&nbsp;bortezomib (Velcade) plus thalidomide (Thalomid; VTd), or the regimen of bortezomib, lenalidomide (Revlimid), dexamethasone (VRd), or other triple-drug combinations going to a 4-drug regimen, including daratumumab.

Videos

Pieter Sonneveld, MD, PhD, discusses how the findings from the phase III CASSIOPEIA trial inform current thinking about treating patients with multiple myeloma.

Pieter Sonneveld, MD, PhD | Authors

Articles

Phase III CASSIOPEIA Impacts Treatment Decisions in Patients With Multiple Myeloma